Publication:
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine.

dc.contributor.authorGutiérrez-Bautista, Juan Francisco
dc.contributor.authorSampedro, Antonio
dc.contributor.authorGómez-Vicente, Esther
dc.contributor.authorRodríguez-Granger, Javier
dc.contributor.authorReguera, Juan Antonio
dc.contributor.authorCobo, Fernando
dc.contributor.authorRuiz-Cabello, Francisco
dc.contributor.authorLópez-Nevot, Miguel Ángel
dc.date.accessioned2023-05-03T14:24:12Z
dc.date.available2023-05-03T14:24:12Z
dc.date.issued2022-03-06
dc.description.abstractThe vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273.
dc.identifier.doi10.3390/vaccines10030402
dc.identifier.issn2076-393X
dc.identifier.pmcPMC8949280
dc.identifier.pmid35335034
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2076-393X/10/3/402/pdf?version=1646566147
dc.identifier.urihttp://hdl.handle.net/10668/21606
dc.issue.number3
dc.journal.titleVaccines
dc.journal.titleabbreviationVaccines (Basel)
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHLA associations
dc.subjectanti-S antibodies
dc.subjectmRNA-1273 vaccine
dc.titleHLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8949280.pdf
Size:
620.62 KB
Format:
Adobe Portable Document Format